**S3 Table. ADRs causing or contributing to admission**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Cardiovascular ADRs\* | Haemorrhage\* | Blood dyscrasias\* | Electrolyte disturbances\* | CNS ADRs\* | Gastorintestinal ADRs\* | Dizziness | Pyrexia | Thrombosis\* | Blood sugar disturbances\* | Angioedema | Drug level increased | Renal impairment\* | Liver disorders\* | Skin ADRs\* | International normalised  ratio increased | Lactic acidosis | Total |
| L01 "ANTINEOPLASTIC AGENTS" | 1 | 4 | 15 |  | 1 | 2 |  | 4 | 2 |  |  |  |  |  | 1 |  |  | 30 |
| B01 "ANTITHROMBOTIC AGENTS" |  | 21 | 2 |  |  |  |  |  |  |  |  |  |  |  | 1 | 1 |  | 25 |
| C09 "AGENTS ACTING ON THE RENINANGIOTENSIN SYSTEM" | 9 |  |  | 6 |  |  |  |  |  |  | 2 |  | 1 |  |  |  |  | 18 |
| C03 "DIURETICS" | 6 |  |  | 9 |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 |
| C07 "BETA BLOCKING AGENTS" | 15 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15 |
| M01 "ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS" |  | 5 | 1 |  |  | 1 |  |  |  |  |  |  | 1 | 1 |  |  |  | 9 |
| C01 "CARDIAC THERAPY" | 4 |  |  |  | 1 |  |  |  |  |  |  | 2 |  |  |  |  |  | 7 |
| L04 "IMMUNOSUPPRESSANTS" |  | 1 | 3 |  |  |  |  | 1 |  |  |  |  | 1 | 1 |  |  |  | 7 |
| N05 "PSYCHOLEPTICS" | 2 | 1 |  |  |  |  | 2 |  |  | 1 |  | 1 |  |  |  |  |  | 7 |
| N06 "PSYCHOANALEPTICS" | 2 | 2 | 1 | 1 |  |  | 1 |  |  |  |  |  |  |  |  |  |  | 7 |
| N02 "ANALGESICS" |  | 1 |  |  | 2 | 2 | 1 |  |  |  |  |  |  |  |  |  |  | 6 |
| A10 "DRUGS USED IN DIABETES" |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  | 1 | 4 |
| H02 "CORTICOSTEROIDS FOR SYSTEMIC USE" |  | 2 | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 |
| J01 "ANTIBACTERIALS FOR SYSTEMIC USE" |  |  |  |  | 3 | 1 |  |  |  |  |  |  |  |  |  |  |  | 4 |
| A12 "MINERAL SUPPLEMENTS" |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |
| C08 "CALCIUM CHANNEL BLOCKERS" | 2 |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  | 3 |
| A11 "VITAMINS" |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
| G03 "SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM" |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  | 2 |
| M05 "DRUGS FOR TREATMENT OF BONE DISEASES" |  |  |  | 1 |  | 1 |  |  |  |  |  |  |  |  |  |  |  | 2 |
| N04 "ANTIPARKINSON DRUGS" |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  | 2 |
| G04 "UROLOGICALS" | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
| H01 "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES" |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
| L02 "ENDOCRINE THERAPY" |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  | 1 |
| N03 "ANTIEPILEPTICS" |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
| Total | 42 | 37 | 24 | 24 | 7 | 7 | 6 | 5 | 5 | 4 | 3 | 3 | 3 | 2 | 2 | 1 | 1 |  |

\*Clinical manifestations of ADRs included in the categories above

**Cardiovascular ADRs**: “arrhythmia”, “cardiac failure”, “hypertension”, “hypotension”, “orthostatic hypotension”, “syncope”

**Electrolyte disturbances**: “hypercalcemia”, “hyperkalemia”, “hypokalemia”, “hyponatremia”

**Hemorrhage:** “epistaxis”, “gastric ulcer”, “gastrointestinal hemorrhage”, “hematemesis”, “hematoma”, “hematuria”

**Blood dyscrasias:** “anemia”, “neutropenia”, “leukopenia”, “febrile neutropenia”, “thrombocytopenia”

**CNS ADRs:** “confusional state”, “depressed level of consciousness”, “hallucination”, “somnolence”, “respiratory depression”, “parkinsonism”, “fatigue” , ”headache”

**Gastrointestinal ADRs:** “constipation”, “diarrhea”, “gastritis”, “vomiting”, “nausea”

**Blood sugar disturbances:** “diabetes mellitus”, “hyperglycemia”, “hypoglycemia”

**Renal impairment:** ”blood creatinine increased”, ”acute renal failure”

**Liver disorders:** “transaminases increased”, “liver disorder” och “hepatic cirrhosis”

**Thrombosis:** “arterial thrombosis”, “pulmonary embolism”

**Skin ADRs:** “pruritus”, “rash”